CSPM EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 2 / No 5 (2023) Natl Sci Open, 2 5 (2023) 20220062 Full HTML
Open Access
Review

Table 1

Summary of therapeutic MBs and NBs for different biomedical applications

Materials Gas types Advantages Size Biomedical applications Reference
Doxorubicin O2 NBs Chemotherapy 184–207 nm MDA-MB-231 breast cancer and Hela cervical cancer [15]
Gas vesicles O2 NBs PDT 300–330 nm SCC7 carcinoma cancer [18]
ICG O2 NBs PDT 220 nm Oral cancer [20]
Biotin functionalised Rose Bengal O2 MBs SDT 1–2 μm BxPc-3 pancreatic cancer [16]
Lipid NO MBs Chemotherapy 1.012 ±
0.712 μm		 Thrombus and ischemia-reperfusion injury [21]
Streptavidin NO MBs Chemotherapy 0.96 ± 0.07 mm Immunosuppressive and anti-thrombotic [22]
Lipid NO MBs Chemotherapy 3.85 μm Proliferation, apoptosis, and migration of the mesenchymal stem cells [28]
H2O2 and L-arginine NO MBs Chemotherapy 2.32 ± 0.21 μm Hyperglycemia theranostics [30]
Lipid Xe MBs Chemotherapy 4.2 ± 0.16 μm Imaging [32]
Lipid Xe NBs Chemotherapy 225 ± 11 nm Acute ischemic stroke [35]
Lipid Xe MBs Chemotherapy Early brain injury [36]
Lipid Xe MBs Chemotherapy Traumatic brain injury [40]
Porphyrin/camptothecin-floxuridine C3F8 MBs
and NBs		 Chemotherapy and PDT 1 μm (MBs)
30 to 100 nm (NBs)		 HT-29 colorectal cancer [43]
Porphyrin derivatives C3F8 NBs SDT 144.66 to 199.5 nm LS 174T colorectal cancer [42]
Rose bengal C3F8 MBs
NBs		 SDT 130 nm (NBs) HT-29 colorectal cancer [46]
Rose Bengal C4F10
MBs		 SDT 1.2–2.2 μm LNCaP-Lucprostate cancer [45]
Folic acid, IR-780 iodide C3F8 NBs PTT 539–643 nm U87 xenografts [48]
Porphyrin, HIF1α-siRNA C3F8 MBs PDT and gene therapy 1 to 7 μm Triple negative
breast cancer		 [45]
Folate C3F8 NBs Physical targeted therapy 80 to 790 nm FR-positive cancer [47]
Doxorubicin C3F8 NBs Chemotherapy about 350 nm Anaplastic thyroid cancer [41]
Platelet membrane SF6 NBs Chemotherapy 246.57 ± 14.32 nm Vascular endothelial injury [56]
Superparamagnetic iron oxide nanoparticles SF6 NBs Chemotherapy 227.40 ± 87.21 nm Ischemic stroke [57]
Cas9/sgRNA protein SF6 MBs Gene therapy 1.19 μm Androgenic alopecia [58]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.